Photodynamic therapy and the development of metal-based photosensitisers.
Josefsen LB, Boyle RW. · 2008
Read Photodynamic therapy and the development of metal-based photosensitisers. by Josefsen LB, Boyle RW. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2535827.txt.
Introduction
Josefsen and Boyle reviewed in 2008 the light-activated drugs used in photodynamic therapy and the push to build better ones from metals. The treatment pairs a light-sensitive drug, a photosensitiser, with light of a chosen colour. The drug gathers in diseased tissue. The light then switches it on to make reactive oxygen species. These aggressive molecules wreck cells and trigger cell death.
The first approved drug, Photofrin, works against eye disease, psoriasis, and some cancers but leaves patients sensitive to light for a long time. The review surveys newer generations built on ring-shaped molecules called cyclic tetrapyrroles, with and without metal centres. It covers which candidates were tested in cells and animals, which reached clinical trials, and which are now used in patients.
Catalog record
| CREATOR | Josefsen LB, Boyle RW. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 83 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Photodynamic Therapy and the Development of Metal-Based Photosensitisers By Leanne B Josefsen, Ross W Boyle Published in: Metal-Based Drugs DOI: 10.1155/2008/276109 ABSTRACT Abstract Photodynamic therapy (PDT) is a treatment modality that has been used in the successful treatment of a number of diseases and disorders, including age-related macular degeneration (AMD), psoriasis, and certain cancers. PDT uses a combination of a selectively localised light-sensitive drug (known as a photosensitiser) and light of an appropriate wavelength. The light-activated form of the drug reacts with molecular oxygen to produce reactive oxygen species (ROS) and radicals; in a biological environment these toxic species can interact with cellular constituents causing biochemical disruption to the cell. If the homeostasis of the cell is altered significantly then the cell enters the process of cell death. The first photosensitiser to gain regulatory approval for clinical PDT was Photofrin. Unfortunately, Photofrin has a number of associated disadvantages, particularly pro-longed patient photosensitivity. To try and overcome these disadvantages second and third generation photosensitisers have been developed and investigated. This Review highlights the key photosensitisers investigated, with particular attention paid to the metallated and non-metallated cyclic tetrapyrrolic derivatives that have been studied in vitro and in vivo; those which have entered clinical trials; and those that are currently in use in the clinic for PDT. 1. PHOTODYNAMIC THERAPY: BACKGROUND The use of light in the treatment of disease has been known for many centuries and can be traced back over 4000 years to the ancient Egyptians [1]. The Egyptian people used a combination of the orally ingested Amni Majus plant and sunlight to successfully manage vitiligo: a skin disorder of unknown cause. The active ingredient of this plant (psoralen, Figure 1) is now successfully employed in the worldwide treatment of psoriasis [1–4]. [Figure: Structure of psoralen.] Photodynamic therapy (PDT) is a treatment involving light and a chemical substance (a photosensitiser), used in conjunction with molecular oxygen to elicit cell death. More explicitly, photodynamic therapy is a selective treatment modality for the local destruction of diseased cells and tissue. The selectivity is based on the ability of the photosensitiser to preferentially accumulate in the diseased tissue and efficiently generate singlet oxygen or other highly reactive species such as radicals, which induce target cell death. The principle of photodynamic therapy is based on a multi-stage process (Figure 2). The first of these stages (Figure 2(a)) sees the administration of a photosensitiser with negligible dark toxicity, either systemically or topically, in the absence of light. When the optimum ratio of photosensitiser in diseased versus healthy tissue is achieved, the photosensitiser is (Figure 2(c)) activated by exposure to a carefully regulated dose of light which is shone directly onto the diseased tissue for a specified length of time. The light dose is regulated in order to allow a sufficient amount of energy to be delivered to activate the photosensitiser, but at the same time the dose should be small enough to minimise damage inflicted on neighbouring healthy tissue. It is the activated form of the photosensitiser which evokes a toxic response in the tissue, resulting in cell death. The success of photodynamic therapy lies in the prolonged accumulation of photosensitiser in diseased tissue, relative to the more rapid clearance from normal tissue cells. [Figure: Photosensitiser administration.] Photodynamic therapy is commonly practiced in the treatment of a number of cancers, including those present in the head and neck, the lungs, bladder, and particular skin cancers [5–16]. It has also been successfully used in the treatment of non-cancerous conditions such as age-related macular degeneration (AMD), psoriasis, atherosclerosis, and has shown some efficacy in anti-viral treatments including herpes [2, 3, 5–7, 9, 17–20]. Photodynamic therapy carries advantages for both the patient and the physician: the need for delicate surgery and lengthy recuperation periods is minimised, along with minimal formation of scar tissue and disfigurement. However, photodynamic therapy is not without its drawbacks: a major limitation is the associated general photosensitisation of skin tissue. 2. HISTORY OF PHOTODYNAMIC THERAPY Reports of contemporary photodynamic therapy came first in the investigations led by Finsen in the late nineteenth century [8]. Finsen successfully demonstrated phototherapy by employing heat-filtered light from a carbon-arc lamp (the “Finsen lamp”) in the treatment of a tubercular condition of the skin known as lupus vulgaris, for which he won the Nobel Prize in Physiology or Medicine in 1903 [8]. But it was not until the early twentieth century that reports of photodynamic therapy for the treatment of cancer patients (with solid tumours) were made by von Tappeiner's group in Munich [2, 4, 6, 9]. In 1913 another German scientist, Meyer-Betz, described the major stumbling block of photodynamic therapy. After injecting himself with haematoporphyrin (Hp, a photosensitiser), he swiftly experienced a general skin sensitivity upon exposure to sunlight—a problem still persistent with many of todays' photosensitisers [2, 3, 7, 18]. Further studies, investigating the accumulation of haematoporphyrin and the purified haematoporphyrin derivative (HpD) in tumours, culminated in the late 1980s with the photosensitiser Photofrin (Figure 3). A photosensitiser which, after further purification, was first given approval in 1993 by the Canadian health agency for use against bladder cancer and later in Japan, USA and parts of Europe for use against certain cancers of the oesophagus and non-small cell lung cancer [3–9, 17, 18, 21, 22]. [Figure: Structure of Photofrin, n = 1–9.] Photofrin was far from ideal and carried with it the disadvantages of prolonged patient photosensitivity and a weak long-wavelength absorption (630 nm) [6, 7, 21]. This led to the development of improved (second generation) photosensitisers, including Verteporfin (a benzoporphyrin derivative, also known as Visudyne) and more recently, third generation photosensitisers based around targeting strategies, such as antibody-directed photosensitisers [4, 5, 7, 18, 19, 23–25]. 3. CYCLIC TETRAPYRROLIC CHROMOPHORES AND PHOTOSENSITISERS Cyclic tetrapyrrolic molecules are good examples of fluorophores (see Glossary) and photosensitisers. Photosensitisers are molecules, which, when excited by light energy, can utilise the energy to induce photochemical reactions to produce lethal toxic agents. In a cellular environment, these agents (reactive oxygen species (ROS) and radicals) ultimately result in cell death and tissue destruction (Figure 4) [5–9]. Photosensitisers are absorbed into cells all over the body and alone are harmless, that is, in the absence of light, and usually oxygen they have no effect on healthy or abnormal tissue. Ideally, they should be retained by diseased tissue, particularly tumours, for longer periods of time in comparison to healthy tissue; thus it is important to carefully time light exposure and ensure that activation only occurs when the ratio of photosensitiser is greater in diseased tissue than in healthy tissue, thereby minimising unwanted damage to surrounding non-cancerous cells [3, 19]. [Figure: Photosensitiser initiated cell death.] Photosensitisers also have alternative applications. They have been employed in the sterilisation of blood plasma and water in order to remove blood-borne viruses and microbes and have been considered for agricultural uses, including herbicides and insecticides [5, 9, 26–28]. 4. PHOTOCHEMISTRY: PHOTOCHEMICAL PROCESSES Only when a photosensitiser is in its excited state (3Psen*) can it interact with molecular oxygen (3O2) and produce radicals and activated oxygen species (ROS), crucial to the Type II mechanism which is thought to predominate in PDT (see below). These species include singlet oxygen (1O2), hydroxyl radicals (•OH), and